Treatment of prostate cancer

TW202641548APending Publication Date: 2026-10-16ORIC PHARMACEUTICALS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115100875
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-11
Filing Date
2026-01-09
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080903_001
    Figure TWG2TA001080903_001
  • Figure TWG2TA001080903_002
    Figure TWG2TA001080903_002
  • Figure TWG2TA001080903_003
    Figure TWG2TA001080903_003
Patent Text Reader

Abstract

or a pharmaceutically acceptable salt thereof, including those methods wherein the mCRPC in the subject has been determined to be resistant to one or more androgen receptor signaling inhibitors (ARSI), including, for example, abiraterone acetate.
Need to check novelty before this filing date? Find Prior Art